DOCSLIB.ORG

Japan's Takeda Acquires Nycomed in C9.6Bn Deal

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Japan's Takeda Acquires Nycomed in C9.6Bn Deal OTC30-05-11p1&28FIN.qxd 26/5/11 07:07 Page 1 30 May 2011 COMPANY NEWS 3 Japan’s Takeda acquires Stada gets to work on 3 two acquisitions Alliance Boots stands up to 4 tough market Nycomed in C9.6bn deal Atrium Innovations boasts 6 double-digit jump in sales Celesio calls for Lloydspharmacy 7 apan’s Takeda Pharmaceutical will sig- The deal will also create a company with an- change Jnificantly increase its presence in Europe nual consumer healthcare sales of nearly C1.0 Self-medication sales grow at Krka 7 and emerging markets when it acquires Ny- billion. Nycomed’s portfolio of OTC products Taisho eyes international expansion 8 comed in a C9.6 billion deal, which excludes – including its non-prescription 20mg panto- BioGaia turns its attention 10 the Swiss firm’s US dermatology unit. Nyco- prazole tablets and its non-prescription calcium towards oral-health brands med’s shareholders have agreed the deal. products – generated sales of C433 million in Actavis looks at diabetes service 10 Acquiring Nycomed, the Japanese firm said, 2010, while Takeda reported Consumer Health- would transform its global business by merg- care turnover of ¥60.3 billion (C525 million) in Valeant snaps up Sanitas 11 in C314 million cash deal ing Takeda’s “strong presence in the Japanese the year ended 31 March 2011. and US markets” with Nycomed’s “significant Non-prescription products will account for GENERAL NEWS 12 business infrastructure in Europe and high- around 6% of the combined business’ annual growth emerging markets”. ■ Continued on page 11 German court rejects Fenistil 12 for cold sores FDA panel recommends 13 acetaminophen changes Pack design draft excessive and negative Study links paracetamol 14 urope’s OTC industry has criticised the selected off the shelf suggests the draft recom- with blood cancer E“excessive requirements” proposed in the mendations are not in the interests of consum- MARKETING NEWS 15 European Medicines Agency’s (EMA’s) draft ers. “Many of the elements rejected or restrict- recommendations on pack design and label- ed in this guideline are key in the appropriate Bayer puts Biseptinespraid 15 ling for non-prescription medicines authorised selection of non-prescription medicines,”re- in free-access through the centralised procedure. marks the firm, adding: “We strongly believe Wartner pen on mission 16 The Association of the European Self-Med- this guideline would reduce correct selection.” to write-off verrucas and warts ication Industry, the AESGP,is also concern- Meanwhile, the OTC industry would like the Twice as fast Aspirin makes 17 ed about the “negative tone” of the draft rec- draft recommendations to cover the permission a worldwide debut in the US ommendations, which were released for con- to put product-specific website addresses on Alcon grows Systane with 18 sultation in March of this year (OTC bulletin, packs, as stated by the European Commission two for dry eyes 15 April 2011, page 10). back in 2008. The AESGP suggests adding a Research by one AESGP member company section to the document permitting “signpost- FEATURES 20 into the way non-prescription medicines are ■ Continued on page 14 OTC firms focus on 20 new directions Procter & Gamble is teaming up with J&J’s Cilag snaps up OTC assets from JB Teva, GlaxoSmithKline is putting itself on a par with the best fast-moving ohnson & Johnson affiliate Cilag Interna- worldwide rights to the Doktor Mom herbal consumer goods companies, and Jtional is set to pay around US$260 million cough brand, Fitovit vitamin range and Rinza Merck & Co and Pfizer are considering (C185 million) for JB Chemicals & Pharmaceu- cough and cold line. their options. Meanwhile, Meda, Reckitt Benckiser and Sanofi have ticals’ OTC business in Russia and the Com- Doktor Mom was one of the most recog- made a string of acquisitions. Deborah monwealth of Independent States (CIS). The nisable brands in Russia, JB pointed out, hav- Wilkes reports. deal also includes worldwide rights to a num- ing been awarded a “Most Trusted European ber of the Indian company’s OTC brands. Brand Award” in the cough and cold segment REGULARS Under the terms of the transaction – which by Russian subscribers to Reader’s Digest on is expected to close by mid-2011 – Switzerland- multiple occasions (OTC bulletin,31 March Events – Our regular listing 19 based Cilag would pay around US$210 million 2008, page 12). People – Regenauer to take helm 27 for the OTC business in Russia and the CIS, Cilag will pay a further US$47 million for of global unit at Merz Pharma JB said, and just over US$1.0 million for the ■ Continued on page 10 OTC30-05-11p2-3FIN.qxd 25/5/11 11:51 Page 3 COMPANY NEWS OTC Mergers & Acquisitions/First-Quarter Results Stada gets to work on two acquisitions tada Arzneimittel has returned to the acqui- of Stada’s executive board, who said recently Stada said turnover at its Branded Products Ssition trail with a vengeance by announcing the firm had replaced its “cautious acquisitions division had risen by 13% to C115 million in the two potential acquisitions that would expand policy” of the past two years with an “accel- first quarter of 2011 (see Figure 1), with non- its presence across most of Europe as well as erated acquisitions approach” (OTC bulletin, prescription products accounting for about 60% the Middle East. 15 April 2011, page 7). of the total. Adjusted for portfolio changes and The German firm said it was in exclusive At the time, Retzlaff noted that the company currency effects, the growth was 10%. Oper- talks to acquire a portfolio of branded products was pursuing three acquisition targets, includ- ating profit at the division increased by 18% to in Central and Eastern Europe and the Middle ing “an Eastern Europe package” and an “inter- C27.6 million. Operating margin grew from East from fellow German firm Grünenthal for esting target not too far from Germany”. Retz- 23.2% to 24.1%. around C360 million. Stada is also keen to hold laff said the company was looking for brands Branded Products’ sales in Stada’s home talks about the possible acquisition of Spirig with “high growth and high margins”. market of Germany – predominantly under the Pharma’s Swiss generics business. Stada is planning to buy a portfolio of 14 Stada and Hemopharm brand names – slipped The two potential deals underline the re- primarily prescription products from Grünen- back by 5% to C34.5 million. They represented marks made by Hartmut Retzlaff, chairman thal. The portfolio consists of six of Grünen- 27% of the group’s sales in the country,which thal’s own brands and eight licensed products, fell by 11% to C127 million (see Figure 2). including the Flexove/Glucomed glucosamine Turnover from Branded Products in Russia OTC bulletin brand, the Oekopharm range of nutritional sup- – Stada’s second biggest market in terms of plements, and a diclofenac patch. sales – increased by 37% to C30.4 million, rep- 30 May 2011 Number 363 Subject to the successful completion of nego- resenting over half of the group’s sales in the tiations and the approval of anti-trust authorities, country,which grew by 22% to C54.5 million. Editor & Publisher: Deborah Wilkes the deal is expected to close by the end of 2011. At constant exchange rates, the rise was 20%. Associate Editors: Aidan Fry Acquiring the Grünenthal brands is in line In the Italian market, Branded Products re- Mike Rice with Stada’s strategy of growing its Branded corded sales up by 2% to C10.1 million, account- Business Editor: Matt Stewart Products business and boosting its presence ing for 26% of Stada’s group sales in the coun- Assistant Editors: Jenna Lawrence in Eastern Europe. try,which improved by 21% to C38.7 million. David Wallace Meanwhile, the potential deal involving Spi- The share was down from 31% in 2010. Advertising Controller: Debi Minal rig Pharma’s Swiss generic business included Group operating profit advanced by 12% to 15 OTC and prescribed non-prescription prod- C57.6 million. Earnings before interest, tax, de- Marketing Manager: Val Davis ucts, Stada noted, along with 56 prescription preciation and amortisation (EBITDA) grew by Editorial, Subscription and Advertising products. The products had estimated annual 5% to C79.8 million. enquiries should be addressed to: OTC bulletin, OTC Publications Ltd, 54 Creynolds Lane, Solihull, sales of SFr45 million (C36 million). OTC West Midlands B90 4ER, UK. Tel: +44 1564 777550. Fax: +44 1564 777524. Business First-quarter sales Change Operating profit Change E-mail: [email protected]. (C millions) (%) (C millions) (%) Subscriptions Generics 293 +5 40 +5 Annual subscriptions to OTC bulletin in Europe are £625.00 for single copies and £355.00 for additional copies to the same ad- Branded Products 115 +13 28 +18 dress, including delivery. Subscriptions to addresses outside Eur- ope are subject to an additional charge of £30.00 to cover postage. Commercial 7-52 1+46 Subscription enquiries in Korea should be directed to Pharma Group/other 4+138 -11 – Koreana Ltd, 14th Floor,KTB Network Building, 826-14 Yeoksam- dong, Kangnam-gu, Seoul 135-080, Korea (Tel: +82 2 554 9591; Total Stada 418 +6 58 +12 Fax: +82 2 563 8289; E-mail: [email protected]). Advertising Advertising rates and data are available on request from the ad- Figure 1: Stada’s sales and operating profit in the first quarter of 2011 by business (Source – Stada) dress above or at www.otc-bulletin.com. About OTC bulletin CountryFirst-quarter ChangeBranded Products’ Branded Products’ OTC bulletin is published 20 times a year by OTC Publications Limited: twice monthly in February,March, April, May,June, Sep- sales (C millions)(%) sales (C millions) share in Stada (%) tember,October and November; and monthly in December,Jan- uary,July and August.
Load more

Recommended publications
  • Acquisition Agreement for Paras Pharmaceuticals -- Current
    Dealdoc Acquisition agreement for Paras Pharmaceuticals Paras Pharmaceuticals Reckitt Benckiser Dec 13 2010 © 2009-2021, Wildwood Ventures Ltd. All rights reserved. Acquisition agreement for Paras Pharmaceuticals Paras Pharmaceuticals Companies: Reckitt Benckiser Announcement date: Dec 13 2010 Deal value, US$m: 730.0 : acquisition value • Details • Financials • Termsheet • Press Release • Filing Data • Contract Details Announcement date: Dec 13 2010 Pharmaceutical Industry sectors: Consumer health Financials Deal value, US$m: 730.0 : acquisition value Termsheet 13 December 2010 Reckitt Benckiser has agreed to buy Paras forINR 32.6 billion (Indian Rupees) (approximately GBP 460 million). RB will finance the transaction from existing facilities. Press Release RB Buys India’s Paras Pharmaceuticals Ltd 13 December 2010 Reckitt Benckiser Group plc (RB) today announces that it has agreed to buy Paras Pharmaceuticals Limited (Paras) forINR 32.6 billion (Indian Rupees) (approximately GBP 460 million) from the current shareholders, including the Patel family and Actis, the emerging markets private equity investor. RB will finance the transaction from existing facilities. Paras is a privately-owned Indian company with a portfolio of leading Indian over the counter Health and Personal Care brands including: Moov, the No 2 topical analgesic pain ointment, D’Cold, the No 2 cold & flu remedy, Dermicool, the No 2 for prickly heat, Krack, the No 1 medicated skin treatment for cracked heels and Itch Guard and Ring Guard anti fungal creams. In addition, Paras has a personal care business led by Set Wet, a leading hair gel and deodorant brand. In the fiscal year ending March 2010, Paras generated net sales of INR 4,014 million, representing a mid-teens average growth rate over the last four years, and operating EBITDA for the same year of INR 1,083 million (approximately GBP 56 million and GBP 15 million respectively).
    [Show full text]
  • Engaged: Unleashing Your Organization's Potential
    “The current economic crisis has underlined how traditional means of manag- ing people are no longer effective. Too many businesses underperform because they can no longer count on the commitment of their workforce. Only by treating employees as key stakeholders and engaging them will organizations be successful. This timely book provides a practical roadmap for companies to create an engaged workforce and is essential reading for all business leaders.” Professor Klaus Schwab, Founder and Executive Chairman, World Economic Forum “This is an important contribution to leaders and managers across all types of organizations. I believe readers of this book will be more confident and better equipped to address the issues their organizations are facing.” David MacLeod, Chairman of the UK Government-sponsored Employee Engagement Task Force and co-author of the influential report to the UK Government Engaging for Success “This book highlights in a very understandable and comprehensive way, one of the most important HR concepts of our age, ‘engagement’. During difficult times, we need more than ever to engage our workforce, to get them involved and committed. This book shows how to do it, and is a ‘must read’ for all line managers and HR professionals.” Cary L. Cooper, CBE, Distinguished Professor of Organizational Psychology and Health at Lancaster University Management School, UK “A must read, timely and practical primer on how to engage any workforce – warts and all.” Will Hutton, author of Them and Us: Changing Britain – Why We Need a Fair Society, Principal at Hertford College, Oxford, UK, weekly columnist at The Guardian and The Observer Newspapers “An engaging book about engagement! Linda and Geoff have produced an au- thoritative book that makes the business case, the emotional case and developed an easy to understand model that will allow HR practitioners and line man- agers to accelerate implementation.
    [Show full text]
  • Employers and Other Organisations Involved in Trailblazers
    Employers and other Organisations Involved in Trailblazers Accountancy – Led by organisations including Baker Tilly, BDO, Costain, Dains, Deloitte, Government Finance Profession, , Ernst & Young, Flemmings, Grant Thornton, Hall and Woodhouse, Harvey & Son, Hazlewoods LLP, Health Education East of England, Kingston Smith, KPMG, Lentells Chartered Accountants, London Borough of Barking and Dagenham, NHS Employers, PwC, Solid State Solutions and Warrington and Halton Hospital NHS Foundation Trust with the Association of Accounting Technicians (AAT), Association of Chartered Certified Accountants (ACCA), Chartered Institute of Management Accountants (CIMA), Chartered Institute of Public Finance and Accountancy (CIPFA) and the Institute of Chartered Accountants in England and Wales (ICAEW). This has developed standards for Professional Accounting Technician and Professional Accountant. Accountancy (Phase 4) – Led by organisations including Derby Hospitals NHS Foundation Trust; Selby Jones Ltd; Shapcotts; Skills for Health Academy (North West); Bibby Ship Management; Jackson Stephen LLP; HFMA; Civil Service; Spofforths LLP; Norse Commercial Services Ltd; Norbert Dentressangle; Charles Wells Limited; TaxAssist Accountants; Mazars; Armstrong Watson; MHA Bloomer Heaven developing standards for Assistant Accountant. Actuarial –Led by organisations including Aon Hewitt, Barnett Waddingham, Grant Thornton, KPMG, Mercer, Munich Re, PwC and RSA with the Institute and Faculty of Actuaries. This has developed a standard for Actuarial Technician. Adult Care – Led by organisations including Barchester Healthcare, Caretech Community Services, Creative Support, Hand in Hands, Hendra Health Care (Ludlow), Hertfordshire County Council, Housing and Care 21, Oxfordshire County Council, Progressive Care, Surrey County Council, West England Centre for Inclusive Living, Woodford Homecare. This will develop the standards for Lead Practitioner in Adult Care, and Leader/Manager in Adult Care.
    [Show full text]
  • Corporate Social Responsibility Report 2016 Walgreens Boots Alliance Is the First Global Pharmacy-Led, Health and Wellbeing Enterprise
    Corporate Social Responsibility Report 2016 Walgreens Boots Alliance is the first global pharmacy-led, health and wellbeing enterprise. Our purpose is to help people across the world lead healthier and happier lives. Our 2016 Corporate Social Responsibility Report covers the fiscal year that ended 31 August 2016. In this year’s report: Overview Marketplace Introduction ...................................................1 Our CSR goals .............................................2 28 Our vision, purpose and values ................3 Our approach to CSR .................................4 Contributing to the United Nations Sustainable Development Goals .............6 Transparency ........................................... 30 Our impact ...................................................8 Ethical Sourcing ...................................... 30 ........................... About our Company ................................. 10 External Stakeholders 31 Stakeholder engagement ....................... 12 Workplace Community 32 14 Employee Health and Wellbeing ........ 34 Equal Opportunities .............................. 36 Health and Wellbeing ............................. 16 Health and Safety ...................................37 Young People ........................................... 17 ...................................... Cancer Programs .....................................20 About this report 38 Data management process ................ 38 Environment Data ............................................................ 38 Community data
    [Show full text]
  • Cfs 2015 (1).Pdf
    Takeda Pharmaceutical Company Limited and its Subsidiaries Consolidated Financial Statements Under IFRSs and Independent Auditor's Report For the year ended March 31, 2015 Takeda Pharmaceutical Company Limited Index Items Page Independent Auditor's Report 1 Consolidated Financial Statements 【Consolidated Statement of Operations】 2 【Consolidated Statement of Operations and Other Comprehensive Income】 2 【Consolidated Statement of Financial Position】 3 【Consolidated Statement of Changes in Equity】 4 【Consolidated Statement of Cash Flows】 6 Notes to Consolidated Financial Statements 1Reporting Entity 7 2 Basis of Preparation 7 3Significant Accounting Policies 9 4Operating Segments 16 5 Selling, General and Administrative Expenses 17 6 Other Operating Income and Expenses 18 7 Finance Income and Expenses 18 8 Income Taxes 19 9 Earnings Per Share 21 10 Other Comprehensive Income 21 11 Property, Plant and Equipment 22 12 Goodwill 23 13 Intangible Assets 24 14 Investment Property 26 15 Other Financial Assets 26 16 Inventories 26 17 Trade and Other Receivables 27 18 Cash and Cash Equivalents 27 19 Assets and Disposal Groups Held for Sale 27 20 Bonds and Loans 28 21 Other Financial Liabilities 29 22 Leases 29 23 Employee Benefits 30 24 Provisions 32 25 Other Liabilities 32 26 Trade and Other Payables 32 27 Equity and Other Equity Items 33 28 Financial Instruments 33 29 Share-based Payments 39 30 Cash Flow Information 43 31 Subsidiaries and Associates 44 32 Related Party Transactions 46 33 Business Combinations 46 34 Contingent Liabilities 46 35 Subsequent
    [Show full text]
  • Marketing Leaders Programme 2014 Inspiring Great Marketing Leaders
    THE MARKETING SOCIETY MARKETING LEADERS PROGRAMME 2014 INSPIRING GREAT MARKETING LEADERS IN AssOCIATION WITH SPONSORED BY CONTENTS Introduction 1 Marketing Leaders Programme 2 Inspiring Bolder Marketing Leadership 3 Programme Outline 5 Module 1: Becoming a Great Marketing Leader 6 Speaker Biographies 9 Module 2: Leading for Commercial Success 13 Speaker Biographies 15 Module 3: Leading Marketing into the Future 17 Speaker Biographies 19 Selection of Participants 20 Booking Information, Cost & How To Apply 21 INTRODUCTION The Marketing Society, together with Brand Learning, has developed the Marketing Leaders Programme as a unique development experience for high potential individuals, who are preparing for marketing leadership roles. Now in its 11th year, this blend of marketing and people leadership skill development, delivered by eminent industry leaders and leadership experts, is designed to help shape the great marketing leaders of tomorrow. THIS year’S 1 SPEAKERS INCLUDE: Andy Bird, Executive Director Craig Inglis, Director of Marketing & Co-Founder Brand Learning John Lewis James Brett, Founder Plant For Peace Bernadette Kennedy, General Manager Retail Fuels Marketing Shell Hugh Burkitt, Chief Executive The Marketing Society Steve Langan, Managing Director & Group Marketing Director Hiscox (UK) Rod Connors, Managing Director The Branded Sport Group, Jill McDonald, President & Chief Executive Ex-Marketing Director Nike (UK & Ireland) Officer McDonald’s Restaurants Martin Deboo, Consumer Goods Analyst Cilla Snowball CBE, Group Chairman
    [Show full text]
  • Alliance Boots Preliminary Results Announcement for the Year Ended 31 March 2010
    Press release 17 May 2010 Alliance Boots Preliminary results announcement for the year ended 31 March 2010 “A strong performance delivering double digit growth in trading profit” Highlights: Group • Revenue, including share of associates and joint ventures, up 9.6% to £22.5 billion • EBITDA, including share of associates and joint ventures, up 9.2% to £1,360 million • Trading profit, including share of associates and joint ventures, up 12.7% to £1,074 million • Underlying profit (after tax) more than doubled to £602 million • Cash generated from operations £1,130 million • Net borrowings reduced by £645 million Health & Beauty Division • Revenue up 5.2% – up 4.5% in constant currency • Trading profit up 8.5% • Boots UK - Like for like retail revenue up 3.0% - ‘your local Boots pharmacy’ roll-out completed - No7 Protect & Perfect Intense Beauty Serum launched • Boots Opticians merged with Dollond & Aitchison Pharmaceutical Wholesale Division • Revenue up 10.3% – up 5.6% in constant currency • Trading profit up 17.2% • Business improvement programme largely completed • Further selective deals with manufacturers Stefano Pessina, Executive Chairman, commented: “Since taking the company private, this is our third consecutive year of double digit trading profit growth. Having invested more than £1 billion over the period, we are confident that we are building a platform for sustained long term growth. “Our strong financial position will enable us to continue to grow both organically and through acquisitions. We are increasingly establishing strategic partnerships with other leading businesses to accelerate our development, both in the UK and other markets.” Andy Hornby, Group Chief Executive, said: “Alliance Boots performed strongly in 2009/10, delivering a double digit trading profit growth, combined with a robust cash flow.
    [Show full text]
  • Rb-Annual-Report-2017.Pdf
    Reckitt Benckiser Group plc(RB) Healthier Annual Report and Financial Statements 2017 Statements Financial and Report Annual Lives, Happier Homes Bringing Our Purpose to Life Reckitt Benckiser Group plc (RB) Annual Report and Financial Statements 2017 RB is inspired by a vision of a world where people are healthier and live better. We continually invest and innovate to find new ways for people to look after themselves, their families and their homes. We believe passionately in doing things the right way and have a culture that pushes us to outperform, every day. Contents Strategic Report Transformation of RB page 01 Highlights 02 Our business model 04 Chairman’s Statement 6 06 Chief Executive’s Statement 10 Strategic objectives, targets and key performance indicators 14 betterbusiness in action 20 bettersociety in action 22 betterenvironment in action 24 Operating review 30 Megatrends 32 Health 34 Hygiene Home Strategy page 36 Financial review 42 Our framework for risk management betterbusiness 10 Governance 52 Board of Directors 56 Executive Committee bettersociety 58 Corporate Governance– Chairman’s Statement 61 Corporate Governance Statement betterenvironment 69 Nomination Committee Report 71 Audit Committee Report 76 Corporate Responsibility, Sustainability, Ethics and Compliance Committee Report Mead Johnson Nutrition Sale of 78 Directors’ Remuneration Report integration RB Food 82 Remuneration Policy at a glance 83 Implementation of specific commitments made to page Shareholders for 2017 84 Annual Report on Remuneration 95 Report
    [Show full text]
  • Medical Products Baxter’S Medical Products* Business Manufactures Products Used in the Delivery of Fluids and Drugs to Patients
    Baxter International Inc. Expanding Capabilities in BioSurgery In 2010, Baxter acquired ApaTech, an orthobiologics company with manufacturing and R&D facilities in the United Kingdom. Apatech’s leading product, ACTIFUSE, a synthetic bone graft material, is marketed in the United States, Europe and other countries around the world, and allows Baxter to enter the emerging bone fusion market. ApaTech’s product Applicator for ACTIFUSE pipeline complements other Baxter capabilities in biosurgery. Also in 2010, Baxter announced FDA approval of TachoSil® (Absorbable Fibrin Sealant Patch) for use as an adjunct to hemostasis in cardiovascular surgery. TachoSil® is the first and only adjunctive hemostatic agent available in the United States that combines a collagen patch with a coating of human coagulation factors. TachoSil® is a patented product of Nycomed, a global pharmaceutical company headquartered in Zurich, Switzerland, and is available in a number of markets outside the United States. Baxter holds exclusive U.S. marketing and distribution rights. Seasonal Influenza Vaccine Latest to Leverage Vero Cell Platform In 2010, Baxter received approval of PREFLUCEL, a vaccine for seasonal influenza, in Austria and the Czech Republic. PREFLUCEL is made using Baxter’s Vero cell culture platform and does not contain an adjuvant or preservatives. Baxter expects to launch PREFLUCEL in other European countries in 2011, PREFLUCEL vaccine and is working with the FDA on licensure in the United States. In addition, Baxter continues to expand its development and licensing activities for PREFLUCEL through direct regional and national licensing processes. In 2010, Baxter announced an agreement with Takeda Pharmaceutical Company Limited in Japan for the development, production and supply of cell culture-based influenza vaccines for the Japanese market.
    [Show full text]
  • DURECT CORPORATION (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-31615 DURECT CORPORATION (Exact name of registrant as specified in its charter) Delaware 94-3297098 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 10260 Bubb Road Cupertino, CA 95014 (Address of principal executive offices, including zip code) Registrant’s telephone number, including area code: (408) 777-1417 Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange on Which Registered Common Stock $0.0001 par value per share The NASDAQ Stock Market LLC Preferred Share Purchase Rights (NASDAQ Global Market) Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES NO Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15 of the Act. YES NO Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period than the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Building an Ethical Small Group (Chapter 9 of Meeting the Ethical Challenges of Leadership) Craig E
    Digital Commons @ George Fox University Faculty Publications - School of Business School of Business 2018 Building an Ethical Small Group (Chapter 9 of Meeting the Ethical Challenges of Leadership) Craig E. Johnson George Fox University, [email protected] Follow this and additional works at: https://digitalcommons.georgefox.edu/gfsb Part of the Business Commons, and the Ethics and Political Philosophy Commons Recommended Citation Johnson, Craig E., "Building an Ethical Small Group (Chapter 9 of Meeting the Ethical Challenges of Leadership)" (2018). Faculty Publications - School of Business. 94. https://digitalcommons.georgefox.edu/gfsb/94 This Article is brought to you for free and open access by the School of Business at Digital Commons @ George Fox University. It has been accepted for inclusion in Faculty Publications - School of Business by an authorized administrator of Digital Commons @ George Fox University. For more information, please contact [email protected]. Building a11 Ethical Small Group Cooperation is the thorough conviction that nobody can get there unless everybody gets there. -AUTHOR VIRGINIA BURDEN TOWER Never underestimate a minority. -BRITISH PRIME MINISTER WINSTON CHURCHILL WHAT'S AHEAD This chapter examines ethical leadership in the small-group context. To help create groups that brighten rather than darken the lives of participants, leaders must foster individual ethical accountability among group members, ensure ethical group interac­ tion, avoid moral pitfalls, and establish ethical relationships with
    [Show full text]
  • Lna 2006 Profiles J.Qxp
    1 | Advertising Age | June 26, 2006 SpecialSpecial ReportReport:100 Profiles LEADING NATIONAL ADVERTISERSSupplement SUPPLEMENT June 26, 2006 100 LEADING NATIONAL ADVERTISERS Profiles of the top 100 U.S. marketers in this 51st annual ranking INSIDE TOP 100 RANKING COMPANY PROFILES SPONSORED BY The nation’s leading marketers Lead marketing personnel, ranked by U.S. advertising brands, agencies, agency expenditures for 2005. contacts, as well as advertising Includes data from TNS Media spending by media and brand, Intelligence and Ad Age’s sales, earnings and more for proprietary estimates of the country’s 100 largest unmeasured spending. PAGE 8 advertisers PAGE 10 This document, and information contained therein, is the copyrighted property of Crain Communications Inc. and The Ad Age Group (© Copyright 2006) and is for your personal, non-commercial use only. You may not reproduce, display on a website, distribute, sell or republish this document, or information contained therein, without prior written consent of The Ad Age Group. Are proud to connect you with the leading CMOs See all the interviews at adage.com/point LAUNCHING JUNE 28 © 2006 Crain Communications Inc. www.adage.com 3 | Advertising Age | June 26, 2006 Special Report 100 LEADING NATIONAL ADVERTISERS SUPPLEMENT ABOUT THIS PROFILE EDITION THE 51ST ANNUAL 100 Leading National the Top 100 ($40.13 billion) and for all measured spending in 18 national media, Advertisers Report crowned acquisition- advertisers ($122.79 billion) in the U.S. Yellow Pages Association contributed ladened Procter & Gamble Co. as the top U.S. ad spending by ad category: This spending in Yellow Pages and TNS Marx leader, passing previous kingpen General chart (Page 6) breaks out 18 measured Promotion Intelligence provided free- Motors Corp.
    [Show full text]